Theranos Inc. received much of its funding from high-profile private investors who weren’t part of the ecosystem that typically backs startups and could see their stakes wiped out by the blood-testing company’s regulatory and technological troubles, people familiar with the matter said. Several large investments from families and individuals helped infuse Theranos with $632 million in its latest funding round, which stretched from...

Source: Wall Street Journal November 29, 2016 00:22 UTC